Homepage
Latest Videos
Latest Videos
Brightcove Home Latest Listing
Breast Cancer
Breast Cancer
Brightcove Cards Listing
Prostate Cancer
Brightcove Cards Listing
Multiple Myeloma
Multiple Myeloma
Brightcove Cards Listing
Popular on MedEnrich
Popular in No name
Prostate Cancer49m 18s
Dissecting the biology of advanced prostate cancer
Advanced prostate cancer is characterized by intricate biological changes, including genetic and epigenetic alterations, as well as shifts in cellular metabolism.
advanced prostate cancer
cellular metabolism
castration-resistant prostate cancer
targeted therapies
improved patient care
1

Dissecting the biology of advanced prostate cancer
Breast Cancer3m 2s
ESR1 Mutation as an emerging clinical biomarker metastatic hormone receptor positive Breast Cancer
Combination of CDK4/6 inhibitors & aromatase inhibitor is recommended for frontline treatment of Hormone receptor positive (ER+ve) Metastatic Breast Cancer. Patients eventually develop disease progression which might be attributed to ESR1 mutations.
biomarkers
esr1 mutation
fulvestrant
hormone receptor positive mbc
serd
1

ESR1 Mutation as an emerging clinical biomarker...
OncoSpecials50m 57s
Understanding Biosimilars -An Expert Perspective
Biosimilars are biologic medicines that are highly similar to an FDA-approved reference product, with no clinically meaningful differences in terms of safety, purity, and potency.
biosimilar
biologics
expert perspective
1

Understanding Biosimilars -An Expert Perspective
Breast Cancer14m 46s
ESMO 2022 Breast Cancer Comprehensive Coverage
View comprehensive coverage of Breast Cancer from ESMO 2022
dose dense adjuvant chemotherapy
esmo
keynote -522
monarch -3 study
1

ESMO 2022 Breast Cancer Comprehensive Coverage
Multiple Myeloma11m 40s
How I Treat Relapsed Refractory Multiple Myeloma
Treating relapsed or refractory multiple myeloma (RRMM) can be complex and typically involves a combination of therapies based on the patient's previous treatments, overall health, and specific disease characteristics.
relapsed refractory multiple myeloma
treatment
combination treatment
1

How I Treat Relapsed Refractory Multiple Myeloma
Multiple Myeloma9m 20s
Integrating Pomalidomide Based Regimens in Multiple Myeloma
Integrating pomalidomide and dexamethasone in the treatment of relapsed or refractory multiple myeloma (RRMM) involves using them as a core regimen, often combined with other agents like bortezomib or monoclonal antibodies for enhanced efficacy.
pomalidomide-dexamethasone
rrmm management
progression-free survival
combination therapies
1

Integrating Pomalidomide Based Regimens in Multiple...
Myelodysplastic Syndromes8m 45s
Current Challenges in MDS Diagnosis and Consequences
Bone marrow examination-based diagnosis of MDS with either biopsy or aspirate remains standard of care but is associated with pain, bleeding, difficulty to use the same in elderly patients and hIgh interobserver variability.
non invasive mds diagnosis
web based mds diagnosis tools
1

Current Challenges in MDS Diagnosis and Consequences
Multiple Myeloma3m 16s
Need of Geriatric assessment in Multiple Myeloma
Majority of Myeloma patients are > 65 years of age at diagnosis & that makes Geriatric Assessment a critical for these patients. Historically we have focused on Cytogenetic & Biochemical evaluation but not so much on geriatric assessment.
geriatric assessment
multiple myeloma
quality of life
1

Need of Geriatric assessment in Multiple Myeloma
OncoSpecials6m 24s
2nd Genenration TKIs for 1st line CP-CML -Selecting Right Patients
Deep Molecular Responses (DMR) in CML can protect from progression.2nd generation TKIs are associated with higher rates of DMR than 1st generation TKIs.
2nd generation tki
deep molecular response
elts high risk
e14a2 transcripts
1

2nd Genenration TKIs for 1st line CP-CML -Selecting...
Prostate Cancer7m 6s
Treating Metastatic Hormone Refractory Prostate Cancer - My Approach
Revised definition of Castration Resistant Prostate Cancer (mCRPC) considers castration range testosterone with either biochemical progression with three consecutive rises in PSA or evidence of radiological progression.
castration resistance
mcrpc
metastatic prostate cancer
prostate cancer
1

Treating Metastatic Hormone Refractory Prostate...
For Pharmacist
For Pharmacist
Brightcove Cards Listing
Webinars
Webinar Cards Listing
Upcoming Webinar
Upcoming Webinar
MedBytes
MedBytes
Medbytes Cards Listing
Notable KOLs
Discover Notable KOLs
BSc (Hons), BM (Hons), MRCP, PhD
M.D., MSCE
M.D.
M.D., MSC
M.D.
M.D.
M.D
MD, MBBCh, MRCP, FRCPath
M.D.
MD, PhD, Msc
MD, PhD
MD
MD, PhD
M.D., M.P.H.
Popular Topics
Popular Topics
Brightcove Most viewed videos Listing
Login
To get access to full MedEnrich experience, please Sign in
Don’t have an account? Register Now
Speakers